Advertisement

Kidney-based in vitro models for drug-induced toxicity testing

  • João Faria
  • Sabbir Ahmed
  • Karin G. F. Gerritsen
  • Silvia M. Mihaila
  • Rosalinde MasereeuwEmail author
Open Access
Review Article

Abstract

The kidney is frequently involved in adverse effects caused by exposure to foreign compounds, including drugs. An early prediction of those effects is crucial for allowing novel, safe drugs entering the market. Yet, in current pharmacotherapy, drug-induced nephrotoxicity accounts for up to 25% of the reported serious adverse effects, of which one-third is attributed to antimicrobials use. Adverse drug effects can be due to direct toxicity, for instance as a result of kidney-specific determinants, or indirectly by, e.g., vascular effects or crystals deposition. Currently used in vitro assays do not adequately predict in vivo observed effects, predominantly due to an inadequate preservation of the organs’ microenvironment in the models applied. The kidney is highly complex, composed of a filter unit and a tubular segment, together containing over 20 different cell types. The tubular epithelium is highly polarized, and the maintenance of this polarity is critical for optimal functioning and response to environmental signals. Cell polarity is dependent on communication between cells, which includes paracrine and autocrine signals, as well as biomechanic and chemotactic processes. These processes all influence kidney cell proliferation, migration, and differentiation. For drug disposition studies, this microenvironment is essential for prediction of toxic responses. This review provides an overview of drug-induced injuries to the kidney, details on relevant and translational biomarkers, and advances in 3D cultures of human renal cells, including organoids and kidney-on-a-chip platforms.

Keywords

Nephrotoxicity Drug-induced kidney injury In vitro models Biomarkers 

Abbreviations

l-DOPA

3,4-Dihydroxyl-l-phenylalanine

ADME

Absorption, distribution, metabolism, and excretion

AIN

Acute interstitial nephritis

AKI

Acute kidney injury

ATN

Acute tubular necrosis

ASC

Adult stem cell

ALP

Alkaline phosphatase

ARB

Angiotensin receptor blocker

ACEI

Angiotensin-converting enzyme inhibitors

ABC

ATP-binding cassette

ADPKD

Autosomal dominant polycystic kidney disease

B2 M

Beta-2 microglobulin

BUN

Blood urea nitrogen

BCRP

Breast cancer resistance protein

CRS

Cardiorenal syndrome

CKD

Chronic kidney disease

CLU

Clusterin

CIHP

Conditionally immortalized human podocyte

ciPTEC

Conditionally immortalized proximal tubule epithelial cell

CysC

Cystatin C

CYP

Cytochrome P450

ESKD

End-stage kidney disease

EMA

European Medicines Agency

ECM

Extracellular matrix

FDA

Food and Drug Administration

GGT

γ-Glutamyl transpeptidase

Gγ-GT

γ-Glutamyl transpeptidase transferase

GFR

Glomerular filtration rate

GMEC

Glomerular microvascular endothelial cell

GST

Glutathione S-transferase

HO

Heme oxygenase

HUS

Hemolytic-uremic syndrome

HRS

Hepatorenal syndrome

HFM

Hollow fiber membrane

hTERT

Human telomerase reverse transcriptase

IVIVE

In vitro-to-in vivo extrapolation

iPSC

Induced pluripotent stem cell

IGFBP

Insulin-like growth factor-binding protein

IVIG

Intravenous immunoglobulin

IRI

Ischemia–reperfusion injury

KIM

Kidney injury molecule

L-FABP

Liver type-fatty acid binding protein

MMP

Matrix metalloproteinase

MTX

Methotrexate

MEM

Microelectromechanical systems

MPS

Microphysiological systems

MCP

Monocyte chemotactic protein

MATE

Multidrug and toxin extrusion protein

MRP

Multidrug resistance protein

NAG

N-Acetyl-β-glucosaminidase

NGAL

Neutrophil gelatinase-associated lipocalin

NSAIDs

Nonsteroidal anti-inflammatory drugs

OAT

Organic anion transporters

OCT

Organic cation transporter

OPN

Osteopontin

P-gp

P-glycoprotein

PBPK

Physiologically based pharmacokinetic

PES

Polyethersulfone

PSTC

Predictive Safety Testing Consortium

RPA

Renal papillary antigen

RPTEC

Renal proximal tubule epithelial cell

RAS

Renin-angiotensin system

RBP

Retinol binding protein

sCr

Serum creatinine

SV40T

Simian virus 40 large T antigen

SDS

Sodium dodecyl sulfate

SLC

Solute carrier family

3D

Three-dimensional

TIMP

Tissue inhibitor of metalloproteinase

TEER

Transepithelial electrical resistance

TFF

Trefoil factor

2D

Two-dimensional

uALB

Urinary albumin

uTP

Urinary total protein

Introduction

The kidneys play an essential role in preserving homeostasis of the body’s internal environment, including regulation of water, electrolyte, nitrogen, and acid–base balances. They also control the red blood cell production and blood pressure (Bello-Reuss and Reuss 1983). Impaired renal function is commonly observed in clinical practice and is often associated with the use of drugs. One-third of all drugs and drug candidates are excreted unchanged from the body by the kidneys, and drug-induced nephrotoxicity accounts for 20% of all episodes that lead to acute kidney failure (Naughton 2008b).

Human kidneys contain around 1 million nephrons. A nephron is composed of different subunits and includes the glomerulus, proximal tubule, loop of Henle, distal tubule, and the collecting duct (Lote 2012) (Fig. 1). All subunits contribute to the excretory function of the kidney in three steps: glomerular filtration, tubular reabsorption, and tubular secretion (Koeppen and Stanton 2013). During glomerular filtration (Fig. 2), blood plasma is filtered in the glomerulus, a bundle of porous capillaries lined by a membrane and specialized epithelial cells, that allows solutes and waste, including drugs and their metabolites, and water to pass through while ensuring larger substances, such as blood cells and proteins, remain in the circulatory system (Holechek 2003). Protein-bound molecules, including drugs, are eliminated by proximal tubular secretion via a well-coordinated process of uptake by the tubular cells at the blood-facing basolateral site and secretion into the tubular lumen. Tubular reabsorption begins as soon as the filtrate enters the lumen of the proximal tubule, and involves the reabsorption of organic nutrients, such as glucose, and hormonal-regulated reabsorption of ions coupled with passive water reabsorption. Megalin and cubilin receptors at the apical membrane are responsible for endocytosis-mediated reuptake of filtered low-molecular-weight proteins, such as β2-microglobulin (Eshbach and Weisz 2017). As the filtrate travels along the nephron, some drugs, hydrogen ions, and ammonia are secreted into the collecting tubule (Feher 2017).
Fig. 1

Human kidney anatomy. External view (a), internal view (b), and its functional unit nephron (c)

Fig. 2

The renal proximal tubule. a Blood plasma solutes and proteins pass through the glomerular filter. Organic and inorganic solutes (in green) are freely filtered by the glomerulus. Some solutes, such as glucose and amino acids (in purple), are reabsorbed completely by the proximal tubule epithelial cells and transferred back to the systemic circulation. Protein-bound metabolites (in orange) are actively secreted by the proximal tubule epithelial cells. b Drug transporters involved in nephrotoxicity. The organic anion transporters OAT1 (SLC22A6) and OAT3 (SLC22A8) are involved in the uptake of known antiviral agents, such as cidofovir, adefovir, and tenofovir, which will then be secreted by MRP2 (ABCC2) and MRP4 (ABCC4) located at the apical side of the membrane. The chemotherapeutic agent cisplatin is imported by OCT2 (SLC22A2) and exported via MATE1 (SLC47A1) and MATE2-k (SLC47A2). P-gp (ABCB1) is involved in the secretion of the immunosuppressant cyclosporin A. Uremic toxins, such as Indoxyl sulfate and kynurenic acid, are uptaken via OAT1 and excreted by MRP2/4 and BCRP (ABCG2) (color figure online)

Even though the main function of the kidney is to excrete waste products from the bloodstream, it is important to mention that the kidney is also a major endocrine organ. Five very important hormones/enzymes are produced by the kidney, viz, 1,25-dihydroxyvitamin D3, erythropoietin, renin, Klotho, and kallikrein (Haussler et al. 2016); (Shimamoto and Iimura 1989). Calcitriol, 1,25-dihydroxyvitamin D3, is activated in the proximal tubule and acts in the reabsorption of calcium, but it is also involved in bone health and in the regulation of parathyroid function (Kumar et al. 2012). Erythropoietin is produced by peritubular capillary endothelial cells in the proximal tubule, and acts by stimulating the production of red blood cells in the bone marrow (Ohana et al. 2013). Renin is secreted by granular cells of the juxtaglomerular apparatus. This enzyme also known as angiotensinogenase is the key factor of the renin–angiotensin system (RAS) that leads to the production of the potent vasoconstrictor angiotensin controlling blood pressure (Lopez and Gomez 2010). Klotho is synthesized and secreted by the distal tubule. Similar to calcitriol, Klotho is involved in the calcium and phosphate homeostasis (Kim et al. 2015). Kallikrein of the renal kallikrein–kinin system is found in the distal tubule, and is involved in the regulation of blood pressure (Kakoki and Smithies 2009).

Due to the complexity of the kidney, as an organ containing specialized structures and multiple cell types, it becomes quite difficult to find a reliable model system to study the effects or toxicity of drugs and their metabolites on this organ. In this review, detailed information on drug-induced kidney injury mechanisms and available in vitro models to predict this with relevant translational biomarkers will be discussed, with an emphasis on novel developments in the field of microphysiological systems that meet the requirements of the 3Rs (replacement, reduction, refinement) of animal experiments for drug safety screenings.

Drug-induced kidney injury

Exposure to various drugs or drug candidates for therapeutic or diagnostic purposes (Fig. 3) could possibly lead to toxicity in the kidney, resulting in damage of the tubules, interstitium, glomerulus, or renal microvasculature, and consequently resulting in various clinical manifestations (Table 1) (Małyszko et al. 2016). About 36% of nephrotoxicity incidence has been attributed to antimicrobials (e.g., aminoglycosides). While in most cases, the drug-induced kidney injury is reversible upon cease of treatment some medications could lead to chronic dysfunction such as papillary necrosis, tubulointerstitial nephritis, or prolonged proteinuria (Choudhury and Ahmed 2006). Nephrotoxicity of most drugs is more severe in patients already suffering from kidney disease (Vervaet et al. 2017).
Fig. 3

Risk of drugs to affect kidney function. a The human body is subjected to a variety of nephrotoxicants, including chemotherapeutics, drugs of abuse, antimicrobials, environmental pollutants, and natural substances, which can induce kidney injury via several mechanisms. b These nephrotoxicants can lead to acute kidney injury (AKI). AKI is characterized by gradual loss of kidney function that, when not properly treated, can lead to irreversible kidney failure. Renal vasoconstriction, intrarenal factors, and obstruction are some of the effects of the nephrotoxicants on the kidney, which will lead to a decrease in the glomerular filtration rate (GFR). An estimation of the GFR is widely used in clinic as an indicator of kidney function

Table 1

Commonly used nephrotoxic drugs and associated toxicities

Therapeutic class

Drugs

Toxic events

References

Anticoagulants

Warfarin, heparin

Renal tissue ischemia

Necrosis

Infarction

Brodsky (2014)

Anticonvulsant

Phenytoin

Acute interstitial Nephritis

Diabetes insipidus

Ghane Shahrbaf and Assadi (2015)

Antidepressant

Amitriptyline

Rhabdomyolysis

Coco and Klasner (2004)

Lithium

Chronic interstitial Nephritis

Glomerulonephritis

Rhabdomyolysis

Azab et al. (2015) and Coco and Klasner (2004)

Antifungal agent

Amphotericin B

ATN

Renal tubular acidosis (RTA)

Electrolyte imbalance

Urinary concentration Defects

Deray (2002)

Antihistamine

Diphenhydramine, doxylamine

Rhabdomyolysis

Coco and Klasner (2004)

Antihypertensive

Hydralazine, minoxidil

Prerenal azotemia

Ejaz et al. (2004)

 

Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers

Renal artery stenosis

Volume depletion

Palmer (2002)

Antimicrobials

Aminoglycosides

Hypomagnesemia

nonoliguric ATN

Chronic tubulointerstitial nephritis

Fanconi syndrome

Lopez-Novoa et al. (2011)

Vancomycin

Acute tubular necrosis

Tubular damage

Htike et al. (2012) and Liu et al. (2015)

Ciprofloxacin

AIN

Crystalluria

Bird et al. (2013)

Penicillin

Glomerulonephritis

Naughton (2008a)

Cephalosporin

Acute interstitial nephritis

Naughton (2008a)

Antiplatelet

Ticlopidine, clopidogrel and quinine

Thrombotic microangiopathy

Renal vascular injury

Medina et al. (2001)

Antiretroviral agents

Cidofovir, adefovir

Proximal tubule damage

Kalyesubula and Perazella (2011)

Tenofovir

ATN

Proximal tubulopathy

Fernandez–Fernandez et al. (2011) and Jafari et al. (2014)

Indinavir

Tubular crystallization

Nephrolithiasis

Kalyesubula and Perazella (2011)

Atazanavir

AIN

Hara et al. (2015)

Antiviral

Valaciclovir

Thrombotic microangiopathy

Renal vascular injury

Izzedine et al. (2005)

Acyclovir

Tubular crystallization

Yildiz et al. (2013)

Foscarnet

Crystal deposition

Electrolyte abnormalities

Frochot et al. (2016)

Bisphosphonates

Bisphosphonate zoledronate

Deranged Na–K-ATPase

Loss of brush border

Apoptosis

Markowitz et al. (2003)

Calcineurin inhibitor

Rapamycin

Tubular collapse

Vacuolization

Nephrocalcinosis

Marti and Frey (2005)

Chemotherapeutic agent

Cisplatin

Proximal tubular necrosis

Tubular cell deletion

Miller et al. (2010)

Nedaplatin

Lysosomal hyperplasia

Necrosis and hyperplasia of renal papilla and collecting duct

Uehara et al. (2011)

Mitomycin C

Thrombotic microangiopathy

Renal vascular injury

Lameire (2014)

Ifosfamide

Proximal tubular Dysfunction

Fanconi-like syndrome

Nissim et al. (2006)

Methotrexate (MTX)

Tubular crystallization

ATN

Widemann and Adamson (2006)

Pemetrexed

ATN

Nephrogenic diabetes insipidus (NDI)

RTA

Zajjari et al. (2017)

Contraceptive

Estrogen containing

Hemolytic uremic syndrome

Choudhury and Ahmed (2006)

Diuretics

Thiazides, loop, potassium-sparing

Prerenal azotemia

Naughton (2008a)

Immunomodulatory

Intravenous immunoglobulin (IVIG)

Osmotic nephrosis

Levy and Pusey (2000)

Immunosuppressive

Cyclosporin

Decreased glomerulus filtration rate

Busauschina et al. (2004)

Cyclosporin, tacrolimus and muromonab-CD3

Thrombotic microangiopathy

Renal vascular injury

Olyaei et al. (2001)

Narcotic analgesic

Cocaine, heroin, methadone

Rhabdomyolysis

Alinejad et al. (2016) and McCann et al. (2002)

Non-narcotic analgesic

Aspirin, acetaminophen

Chronic interstitial nephritis

Sampathkumar et al. (2016)

Nonsteroidal anti-inflammatory drugs

Glomerulonephritis

Acute interstitial nephritis

Chronic interstitial nephritis

Prerenal azotemia

Acute papillary necrosis

Membranous nephropathy

Lucas et al. (2019) and Naughton (2008a)

Osmotic agents

Mannitol, dextran

Isometric vacuolization

Swelling of proximal tubule

Choudhury and Ahmed (2006)

Thrombolytic agents

Streptokinase and tissue-plasminogen activator

Renal tissue ischemia

Necrosis

Infarction

Eddy and Fogo (2006)

Kidneys can experience both structural damage and loss of function

Acute kidney injury (AKI) is characterized by an increase in blood levels of waste solutes, such as urea and creatinine, and often oliguria and electrolyte disorders. AKI can be classified into three categories: prerenal, intrinsic, and postrenal (Makris and Spanou 2016). In prerenal AKI, the kidney may function normally, but there is a decrease in either intravascular volume or arterial pressure, which results in a reduced glomerular filtration rate (GFR) (Macedo and Mehta 2009). RAS inhibitors such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers can also lead to prerenal AKI, as it causes dilation of the efferent arteriole which contributes to reduced intraglomerular pressure (Navis et al. 1996). Furthermore, nonsteroidal anti-inflammatory drugs (NSAIDs) are known to decrease the GFR by changing the balance of vasodilatory/vasoconstrictive agents in the renal microcirculation (Dixit et al. 2010). The most common type of intrinsic AKI is acute tubular necrosis, which is usually caused by ischemia or toxic injury (Basile et al. 2012). Postrenal AKI occurs when there is an obstruction of urinary flow that can lead to impaired renal blood flow and inflammatory processes, seen for example in urate and oxalate imbalances (Makris and Spanou 2016).

When these changes become persistent both in structure and function, AKI may progress to chronic kidney disease (CKD), and when not properly treated, it can lead to end-stage kidney disease. The GFR is used to categorize CKD in five distinct stages, along with the presence or absence of proteinuria (Kipp and Kellerman 2009).

Nephrotoxicants, including chemotherapeutics, drugs of abuse, antimicrobials, radiocontrast agents, environmental pollutants, and natural substances, can induce kidney injury via similar mechanisms. Renal cell death can be mediated by drug transporters that determine the selectivity for the tubular cell, mitochondrial damage, and drug metabolism (Barnett and Cummings 2018). The reabsorption of solutes by the kidneys is a task that demands a large consumption of energy. The proximal tubule is the nephron’s segment that is the most susceptible to toxic effects due to its role in absorption and secretion, both requiring high rates of oxidative metabolism. For this reason, mitochondrial damage will lead to a reduction in ATP production that in turn will increase oxidative stress, disrupt cell volume, ion concentrations, and apoptosis or, in severe cases necrosis, thus compromising renal function (Eirin et al. 2017). Renal transporters may facilitate drugs to enter the tubular cells, sometimes followed by metabolism leading to their bioactivation (Liang et al. 2015a). These transporters belong to two large families: the solute carrier family (SLC) and the adenosine triphosphate (ATP)-binding cassette (ABC) transporter family. Uptake of organic anions (Fig. 2) is mediated by the organic anion transporters 1 (OAT1; SLC22A6) and 3 (OAT3; SLC22A8) and their removal from the cell via breast cancer resistance protein (BCRP; ABCG2), multidrug resistance protein 2 (MRP2; ABCC2) and 4 (MRP4; ABCC4) (Giacomini et al. 2010; Nigam 2018; Nigam et al. 2015). Organic cations (Fig. 2) are transported into tubular cells predominantly via the basolateral organic cation transporter 2 (OCT2; SLC22A2) and then excreted into the tubular lumen via multidrug and toxin extrusion protein 1 (MATE1; SLC47A1) and 2-k (MATE2-k; SLC47A2) and P-glycoprotein (P-gp; ABCB1). Although most drugs are metabolized by the liver, some nephrotoxicants are known to be dependent on kidney metabolism as this organ also expresses Phase I (CYPs) and Phase II (GSTs) enzymes (Anders 1980).

Vascular injury

Several immunosuppressive agents such as cyclosporin, tacrolimus, and muromonab-CD3 may cause renal vascular injury by damaging primary endothelium that induces platelet aggregation and consumption. Such an effect is also associated with antiplatelet agents, for instance, ticlopidine and clopidogrel, and chemotherapeutic agents (e.g., mitomycin C and gemcitabine; Table 1) (Choudhury and Ahmed 2006). The narrow arteries of the kidney including glomerular capillaries, and interlobular and arcuate arteries can be clogged by arterial cholesterol plaques following administration of thrombolytic agents (e.g., streptokinase) and anticoagulants (e.g., warfarin). This can result in ischemia, infarction, necrosis, and inflammation of the surrounding interstitium, often also affecting tubular cells leading to acute tubular necrosis (ATN; Table 1) (Hitti and Anderson 2005).

Tubular injury

Proximal tubule cells absorb and concentrate compounds from the glomerular filtrate as well as from the systemic circulation, and are prone to be affected by nephrotoxic drugs. These drugs can cause tubular toxicity by various mechanisms such as oxidative stress, diminishing mitochondrial function, restricting tubular transport processes, and generating oxidative stress (Perazella 2005). Drugs such as antimicrobials, chemotherapeutics, radiocontrast agents, immunosuppressives, and bisphosphonates are associated with tubular injury. These xenobiotics disrupt tubular cell polarity which, along with the expression of apical and basolateral transporters, is crucial for tubular cell function. This leads to the dislocation of apical and basolateral transporters (e.g., Na/K-ATPase) resulting in a leaky epithelium. Furthermore, subsequent increase in intracellular calcium disrupts ion homeostasis, leading to cell death (Lameire et al. 2005).

Inflammation

Induction of inflammatory responses in the glomerulus, renal tubular cells, and the surrounding interstitium is another mechanism of drug-induced nephrotoxicity that can lead to fibrosis and renal scarring (Naughton 2008b). An immune-mediated inflammatory condition, glomerulonephritis, has been reported to be induced by several medications such as penicillin and NSAIDs (Table 1) and is associated with proteinuria (Frazier and Obert 2018). Inflammation can also be a complication of lithium, although less well known than its tubulotoxic effects. Another inflammatory condition, acute interstitial nephritis (AIN), occurs as adverse reaction to several drugs that are assumed to induce an immune response by binding to the antigens in the kidney. Medications such as antimicrobials, phenytoin, proton-pump inhibitors, allopurinol, lithium, and antivirals have been implicated in this condition (Rossert 2001).

Crystal nephropathy

Various drugs and their derivatives may lead to precipitation of crystals within the distal tubular lumen because of their insolubility in urine, thereby restricting urine flow and triggering a cellular reaction in the interstitium. Renal insufficiency and intravascular volume depletion increase the risk of crystal nephropathy. Concentration of the drug in the urine and urinary pH may influence the precipitation of crystals and volume repletion and adjustment of urinary pH, improving solubility, may be of benefit. Medications associated with crystal nephropathy include antivirals and antimicrobials as mentioned in Table 1 (Markowitz and Perazella 2005).

Patient-specific risk factors

Some patients are more susceptible to develop drug-induced nephrotoxicity. Volume depletion increases the risk by changing the drug concentration to a toxic level. Hypoalbuminemia, commonly observed in cirrhotic patients, increases the risk of unwanted drug overdose by elevating the serum concentration of the unbound drug fractions (Pazhayattil and Shirali 2014). Both elderly and neonates possess a particular risk for drug-induced nephrotoxicity. Comorbid conditions and administration of multiple nephrotoxic drugs carry a significant burden to elderly patients, while premature delivery predisposes neonates to develop kidney function impairment (Patzer 2008). In addition, individual genetic makeup, responsible for variable metabolic pathways and related drug sensitivity, can also influence the vulnerability of kidneys to nephrotoxicants. Polymorphisms in genes encoding enzymes that are involved in drugs’ metabolism and elimination processes may increase the risk of nephrotoxicity. For instance, polymorphism of cytosolic glutathione-S-transferase (GST) enzyme elevates the risk for cisplatin-induced nephrotoxicity, since this enzyme can, to a certain extent, detoxify reactive molecules (Petros et al. 2005). A systematic review on inter-individual differences in cisplatin-induced nephrotoxicity has recently pointed towards three genes (SLC22A2, and two DNA repair genes) that determine sensitivity, suggesting that patient-specific dose optimization can be applied according to the genetic makeup. This approach could possibly reduce cisplatin toxicity (Zazuli et al. 2019).

Kidney failure due to remote organ damage

Several risk factors such as genetics, obesity, diabetes, cardiovascular disease, and age can increase the chances of an individual to develop kidney disease, or when already diagnosed, it can gradually drive the progression of the disease (Kazancioğlu 2013). It is important to note that renal dysfunction can also be affected by the performance of distinct organs, such as the heart, lung, and liver. As the kidneys receive ~ 25% of the cardiac output, a condition known as cardiorenal syndrome (CRS) can manifest when either the heart or the kidneys fail (Ronco et al. 2012). Considering that some segments of the nephron are highly sensitive to oxygen variations, if the lung is injured it can cause severe hypoxemia which in time can reduce renal blood flow, contributing to renal impairment as well (Basu and Wheeler 2013). Patients suffering from cirrhosis can develop hepatorenal syndrome (HRS), which can lead to damage and degeneration of the kidney. If the hepatic metabolism is compromised, a downregulation of cytochrome P450 (CYP) enzymes activity can lead to an accumulation of nephrotoxic drugs in the systemic circulation, resulting in kidney injury (Lane et al. 2013).

Biomarkers for drug-induced kidney injury

Creatinine and urea have long been considered as the “gold standard” to identify drug-induced nephrotoxicity and to detect renal dysfunction. However, various limitations of these two biomarkers, including low sensitivity and specificity, delayed rise in plasma because of functional reserve, and extrarenal clearance, demand for novel renal biomarkers to early detect and monitor drug-induced nephrotoxicity with high specificity and sensitivity. To address this, new potential markers are continuously being developed and qualified, resulting in a substantial increase of biomarker research (Xie et al. 2013). Until now, several biomarkers have been identified, as enlisted in Table 2. A biomarker qualification data submission released by the Predictive Safety Testing Consortium (PSTC) in 2009 included urinary kidney injury molecule-1 (KIM-1), urinary trefoil factor 3 (TFF-3), urinary beta-2 microglobulin (B2 M), urinary cystatin C (CysC), urinary albumin (uALB), urinary total protein (uTP), and urinary clusterin (CLU) as emerging biomarkers to study xenobiotic-induced kidney injury in rat (Dieterle et al. 2010b). Later in 2014, with the support of Food and Drug Administration (FDA) and European Medicines Agency (EMA), the PSTC included neutrophil gelatinase-associated lipocalin (NGAL) and osteopontin (OPN) for further evaluation as emerging biomarkers (Dieterle et al. 2010b).
Table 2

Overview of renal toxicity biomarkers

KIM-1, a sensitive and specific damage marker of proximal tubule epithelial cells, can cleave and move into the tubule lumens upon diverse primary and secondary renal damages. It is found up-regulated in CKD with renal fibrosis and is significantly elevated in early stages of AKI. It is considered an early marker for detection, progression, and outcome of kidney diseases. However, increased KIM-1 may also play role in renal tubular epithelial cells’ regeneration after acute injury (Xie et al. 2013; Yin and Wang 2016). One of the least studied, biologically qualified urinary markers is TFF3, which is reduced significantly in a time- and dose-dependent manner following proximal tubular damage. This small peptide hormone is also found to correlate with the severity of kidney lesions and is considered as a sensitive marker for AKI (Yu et al. 2010). B2M is a low molecular-weight protein filtered completely and almost completely reabsorbed by the proximal tubule. Therefore, a significant increase of B2M is observed in urine following a minor impairment in tubular uptake. Thus, urine B2M is considered as a potential indicator of impaired function during drug-induced nephrotoxicity. In addition, glomerular injury can also elevate urinary excretion of B2M and it has, therefore, been qualified as glomerular injury marker as well in rodents (Dieterle et al. 2010a). Contrary to the conventional renal function biomarkers, CysC exhibits high sensitivity and specificity in monitoring acute and chronic renal impairments. Determination of CysC levels can be used to diagnose early stages of renal dysfunction and to monitor functional alterations over time. This biomarker is considered a better diagnostic tool for pre-clinical renal disease and is found to be a more accurate detector of early stage diabetic nephropathy (Onopiuk et al. 2015). Its plasma level is used as glomerular marker for GFR and the urine level as functional marker of proximal tubule, since it is a low-molecular-weight protein that needs to be reabsorbed by megalin. Urinary albumin (uALB) has been considered a well-established diagnostic and prognostic marker to study the extent of glomerular injury in CKD. Because of its specificity to intrinsic causes such as rhabdomyolysis and ischemic–reperfusion, it remains unchanged in prerenal and postrenal events of AKI (Bolisetty and Agarwal 2011).

Another early marker of renal damage is urinary clusterin (CLU), which is a heterodimeric glycoprotein that contributes to cellular interaction, lipid transport, and initiation of apoptosis during renal damage. Like KIM-1, expression of CLU is significantly elevated in dedifferentiated tubular cells during AKI but also in polycystic kidney disease, nephrectomy, and renal cell carcinoma (Hidaka et al. 2002). This marker has been found as a promising indicator of tubulointerstitial renal lesions and able to predict end-stage kidney disease (ESKD) (Wu et al. 2018), and also helps in triaging of patients with delayed graft function in less than 4 h after transplantation (Pianta et al. 2015). A lysosomal enzyme of proximal tubule, N-acetyl-β-glucosaminidase (NAG), is a persistent, sensitive, quantitative and robust biomarker of proximal tubular injury. It has been found elevated following kidney diseases such as AKI, diabetic nephropathy, and chronic glomerular diseases (Vaidya et al. 2008a). Some other enzymes, such as GST, γ-glutamyl-transferase (GGT), and alkaline phosphatase (ALP), released from proximal and distal tubule cells into urine relate to early damage. In AKIs, two subtypes of GST, α and π, are released from proximal and distal tubule, respectively, allowing to distinguish between the two segments when affected (Wang et al. 2018). As GGT and ALP increase during damage in the brush border, elevated levels of these enzymes were associated with complicated pyelonephritis and renal impairment (Han et al. 2019).

Models for nephrotoxicity screening

Conventional in vitro models

Until recently, researchers were left with only two options: in vitro cultures of primary human cells or the use of animal models, both having limitations. Primary cells are used as they mimic the physiological state of cells in vivo most closely; however, these cells have a limited growth capacity and tend to lose their phenotype over time (Table 3). Despite these limitations, primary renal cells still remain a reliable option to study basic renal cellular functions and the effects of nephrotoxicants thereon. To overcome the difficulty in culturing primary cells, immortalized cells can be used because of their capacity to grow and divide indefinitely. The disadvantages of these cells include the immortalization procedure that by itself may result in some changes that, over time, can alter the functions and characteristics of cells (Bajaj et al. 2018). Animal models are used as they can fill the gap that in vitro models often have, viz, the lack of physiological resemblance. However, the use of animal models is expensive, requires a lot of time and expertise, has low throughput potential, poses ethical issues, but most importantly, these models often do not correlate to human systems (Barré-Sinoussi and Montagutelli 2015).
Table 3

In vitro models for toxicity screening

 

Species

Characteristics

Pros

Cons

References

Primary

 RPTEC

Human

Morphology

 Cuboidal with a characteristic pattern of swirled cells

Markers

 Complete expression of transporters and metabolic enzymes

Function

 Active transepithelial transport function

 Polarized tight monolayer formation

Preserve genetic and phenotypic aspects of the tissue of origin

Easy to isolate

Compatible with high-throughput screening and advanced imaging techniques

Cell sourcing problems

Inter-donor variability

Functional changes during passages

Low lifespan

Low predictivity

Stray et al. (2013), Uetake et al. (2014) and Breda et al. (2019)

 HRMC (mesangium)

Human

Markers

 Fibronectin, Thy-1, smooth muscle actin

 Study IgA nephropathy

Rodriguez-Barbero et al. (2000) and Liang et al. (2015b)

 HRCEpiC (renal cortical)

Human

Markers

 Cytokeratin 18, 19, vimentin

Function

 Production of IL-8

 Inflammation (IL-2Ra and MHC II)

Schmouder et al. (1992) and Lee et al. (2014)

 aProximate™

Human, rat, mouse

Morphology

 RPTEC

Markers

 MDR1, MRP2/4, BCRP, OCTN1/2, OAT1/2/3/4, OCT2/3, OATP4C1

Function

 Net secretion of substrates

 Calcein efflux via MRP2

 BCRP and MDR1 activity (Hoechst 33342 dye)

Brown et al. (2008a, b) and Jenkinson et al. (2012a)

 Kidney slices

Human, rat, mice, dog

Retain the multicellular, structural, and functional features

Damage from cutting

Heterogenous population

De Kanter et al. (1999; Kowalkowski et al. 2017) and Arakawa et al. (2017)

 Isolated perfused kidney

Rat, mouse

Tubulovascular integrity

Short lifespan

Lower levels of filtration rate and ion reabsorption

Not suitable for routine studies

Georgiev et al. (2011)

 Isolated perfused nephrons

Rat, rabbit

Knowledge on location of enzyme systems, metabolic pathways, and distribution of receptors

Not suitable for routine studies

Schafer et al. (1997)

Immortalized cell lines

 RPTEC/TERT1

Human

Morphology

 Functional tight junctions, dome formation, microvilli and primary cilium

Markers

 Aminopeptidase-N, E-cadherin, MRP2, MRP4, OAT4, MDR1, MATE1, OCTN2, OCT3

Function

 Response to PTH treatment by increased cAMP levels

 Gamma glutamyl-transferase activity

 Megalin/cubilin transport system

Enhanced proliferative capacity

Differences in morphology and function

Possible inclusion of ECM

Compatible with high-throughput screening and advanced imaging techniques

Cost-effective

Absence of OAT1 and OAT3 anion importers

Aschauer et al. (2015), Wieser et al. (2008), Wilmes et al. (2015) and Secker et al. (2019)

 ciPTEC

Human

Morphology

 Formation of tight junctions

Markers

 Aminopeptidase-N, Pgp, AQP1, dpp-IV, MRP2/4, OCT2, OAT1, OAT3, BCRP, MATE1/2, CaSR, Megalin/Cubilin receptors

Function

 ALP activity, Albumin endocytosis, sodium-dependent phosphate uptake, OCT2 and P-gp activity, UGT activity

Absence of SGLT2

Jansen et al. (2014), Nieskens et al. (2016) and Wilmer et al. (2010)

 HK-2

Human

Morphology

 Cuboidal morphology, contact inhibition, dome formation, and microvilli

Markers

 Vimentin, cytokeratin, α3β1 integrin, leucine aminopeptidase, fibronectin, MCT1, MDR1, OATP4C1

Function

 Gluconeogenesis, and Na+-dependent glucose uptake

 GGT and alkaline phosphatase activity

 Increased cAMP levels in response to PTH

 Synthesis and secretion of plasma proteins

Does not represent a good model for the study of key renal uptake transporters

Low predictivity

Ryan et al. (1994), Zhao et al. (2017), Jenkinson et al. (2012b) and Murphy et al. (2017)

 Nki-2

Human

Epithelial and proximal tubule phenotype

Markers

 E-cadherin, CK8/18/19, GGT1, OAT1, OAT4

Function

 Production of cAMP in response to PTH, ADH

 GGT and LAP activity

 Absorption of glucose in the presence of NaCl

Limited data available

Desrochers et al. (2013)

 CIHP-1

Human

Morphology

 Foot processes, and slit-diaphragm-like structures

Markers

 Synaptopodin, nestin, CD2AP, nephrin, podocin, WT1, podocalyxin, P-Cadherin, α, β, γ-catenin

Limited data available

Sakairi et al. (2010)

Stem cell-derived

 ESC/iPSC

Human

Markers

 N-cadherin, KSP-CAD, AQP1/2/3, Megalin/Cubilin, GLUT1, OCT2, MDR1, GGT, OAT1/3, PODXL, UMOD

Function

 Citrin uptake by OAT1/3 (inhibited by probenecid)

Easy to isolate (iPSC)

Possible inclusion of ECM

Study molecular mechanisms of diseases

Enables personalized medicine

Ethical issues (ESC)

Low sensitivity

Extensive protocol

Lam et al. (2014), Mae et al. (2013), Kandasamy et al. (2015) and Takasato et al. (2014)

 Organoids

Human

Markers

 PODXL, WT1, LTL, E-cadherin, UMOD, SIX2, PAX2, JAG1

Function

 Transport of fluorescent compounds (lucifer yellow, rhodamine-conjugated dextran, fluorescein methotrexate)

Inclusion of ECM

Heterogenous population

Epithelial cell polarization

Enables personalized medicine

Heterogenous population

Difficult access to apical compartment

Batch-to-batch variability of Matrigel

Xia et al. (2014), Freedman et al. (2015) and Takasato et al. (2015)

Others

 Kidney-on-a-chip

Human

Resemble kidney proximal tubules (tubular conformation and active transepithelial transport)

Increased physiological relevance (3D structures, ECM, multiple compartments)

Exposure to fluid flow and sheer stress

Suitable for studying transepithelial transport

Prototype

Require external tube and pump connection

Made of materials that absorb hydrophobic compounds

Not suitable for routine studies

Jang et al. (2013), Wilmer et al. (2016), Weber et al. (2016), Lee and Kim (2018) and Schutgens et al. (2019)

 Bioartificial kidney tubules

Human

Morphology and markers

 ciPTEC

Function

 Polarized secretion of immune modulators (upon LPS stimulation)

 Transport of organic anions and cations

 Reabsorption of albumin

 Diffusion of FITC-Inulin

Inclusion of ECM

Epithelial cell polarization

Suitable for studying transepithelial transport

Exposure to fluid flow and sheer stress

Only basolateral perfusion

Low–high throughput

Not suitable for routine studies

Jansen et al. (2015, 2016a) and Chevtchik et al. (2018)

 Decellularized kidney

Rat

Recellularization

 ciPTEC

Markers

 ZO-1, AQP1, CLDN-2, OCT2, MATE-1, MATE-2K, OAT1, MRP4, P-gp, BCRP, GLUT1, OATP4C1

Function

 OCT2 activity (ASP+)

Native scaffold

Improved cell function

Homogenous cell population

No fluid shear stress included

Fedecostante et al. (2018)

Being the proximal tubule a major target for many nephrotoxicants, it is logical that cell-based in vitro models that seek to resemble this segment of the nephron should be characterized by the expression of important markers, including SLC22A6 (OAT1), SLC22A8 (OAT3), SLC22A2 (OCT2) on the basolateral membrane and ABCB1 (P-gp), SLC47A1 (MATE1), SLC47A2 (MATE2), ABCC2 (MRP2), ABCC4 (MRP4), ABCG2 (BCRP), and the endocytosis receptors megalin and cubilin on the apical membrane (Bajaj et al. 2018) (Fig. 2). Although often applied, the immortalized HK-2 cell line lacks the expression of OAT1, OAT3, OCT2, MRP2, and BCRP, and may be not a representative model to study nephrotoxicity (Jenkinson et al. 2012b).

Two important immortalized cell lines have been extensively used for nephrotoxicity screening: RPTEC/TERT1 and ciPTEC. The RPTEC/TERT1 cell line was immortalized using the human telomerase reverse transcriptase (hTERT) (Simon-Friedt et al. 2015), whereas ciPTEC lines obtained either from urine or kidney tissue were transfected using hTERT and a temperature-sensitive mutant of SV large T antigen (SV40T), allowing these cells to proliferate at 33 °C and mature at 37 °C (Jansen et al. 2014; Wilmer et al. 2010) (Table 3). These cell lines surpass HK-2 cells by expressing all relevant markers cited above; however, OAT function was only attained after lentiviral transduction (Nieskens et al. 2016). Using the same immortalization procedure in the ciPTEC line, a podocyte cell line (CIHP) was generated. As these cells maintain the filtration barrier of the glomeruli, it is expected that they will also be targets of nephrotoxicants that can ultimately lead to nephrotic syndrome, although no data are as of yet available on drug effects in this cell line (Sakairi et al. 2010).

Toxicity assays mainly focus on measuring cell death; however, renal toxicity can also be manifested by changes in cell polarity, membrane integrity, and mitochondrial function. With this in mind, Sjögren et al. developed a machine learning model that allowed screening of 62 drugs in which ciPTEC-OAT1 cell line was used to predict their nephrotoxicity based on multiple parameters (Sjögren et al. 2018). Similarly, Secker et al. made use of the RPTEC/TERT1 cell line to evaluate transepithelial transports in a small set of known nephrotoxic and non-nephrotoxic drugs, demonstrating that further evaluation of functional parameters, including transepithelial electrical resistance (TEER), reabsorption, and secretion of solutes, is essential to understand the nephrotoxicity mechanisms of drugs and predict the in vivo implication in regards to kidney performance (Secker et al. 2019).

Advanced in vitro models

To bypass the limitations of 2D cultures, advanced in vitro culture systems have been developed, including the use of 3D organized structures, known as organoids, and kidney microphysiological systems (MPS) that can recreate fluidic characteristics found in vivo (Fig. 4). Organoids can be cultured from different sources of stem cells, including embryonic stem cells (ESC), induced pluripotent stem cells (iPSC), and adult stem cells. Due to ethical concerns regarding the culture of embryonic stem cells, iPSCs and adult stem cells are preferred. Using human iPSC cells (Table 3), it is possible to generate kidney organoids that contain cell types from different nephron segments; however, the generated cells are not fully mature (Takasato et al. 2015). To overcome this problem, Chuva et al. developed a two-step protocol in which kidney organoids were transplanted into a chick chorioallantoic membrane to provide a vascularized environment that is necessary for the further maturation of the organoids (Chuva de Sousa Lopes 2019). Examples of other 3D culture systems include RPTEC/TERT1 and Nki-2 cells that, when cultured in Matrigel or Matrigel mixed with collagen I, respectively, were able to further mature and form tubular structures as seen in vivo. Both models showed increased sensitivity to known nephrotoxic drugs when compared to 2D cultures (Desrochers et al. 2013; Secker et al. 2017).
Fig. 4

Schematic figure of the different in vitro models developed for use in nephrotoxicity screenings

In line with these 3D culture systems, a bioengineered kidney tubule was developed that mimics the physiological geometry of the nephron segment. Briefly, ciPTEC-OAT1 cells were seeded onto polyethersulfone (PES) hollow fiber membranes (HFM; Table 3), previously double-coated with 3,4-dihydroxyl-l-phenylalanine (l-DOPA) and collagen IV. Using this system, the excretion of protein-bound uremic toxins and reabsorption of albumin were shown under perfusion conditions, thus mimicking the in vivo situation (Jansen et al. 2015, 2016b) and revealing a remote sensing and signaling pathway to balance microbial metabolite levels in the human body (Jansen et al. 2019). Furthermore, attenuation of uremic toxin-induced damage by vitamin D activated by the bioengineered kidney tubules was demonstrated (Mihajlovic et al. 2017). The use of decellularized kidneys (Table 3) can also be a suitable platform for studying drug-induced nephrotoxicity. Fedecostante et al. decellularized surplus rat kidneys using sodium dodecyl sulfate (SDS) and recellularized these with ciPTEC-OAT1. An increased sensitivity to cisplatin, tenofovir, and cyclosporin A was shown for this model as compared to the 2D system (Fedecostante et al. 2017).

For further improvement of these in vitro models, implementation of fluid flow and vasculature is crucial, not only to increase maturation of the kidney cells but also to provide an environment that more closely resembles the in vivo situation. Flow in tubular lumens varies between 0.2 and 2.0 dyne/cm2 (Cai et al. 2000) and triggers mechanosensitive pathways via microvilli, primary cilia, and the glycocalyx, all expressed at the tubular apical membrane (Raghavan and Weisz 2016). Advances in microelectromechanical systems (MEMs) allowed researchers to apply microfluidics in cell and tissue cultures that resulted in the so-called organ-on-a-chip (Table 3). Vriend et al. demonstrated that culturing ciPTEC-OAT1 in an OrganoPlate, a 3D platform consisting of 96 chips that provides fluid shear stress by placing the plate on a rocker platform, it was possible to create a high-throughput screening method compatible with advanced imaging techniques (Vriend et al. 2018). Following a similar approach, Schutgens et al. developed a new microfluidic in vitro system using kidney tubular epithelial organoids, or “tubuloids”, derived from adult stem cells. The generated tubuloids showed active transepithelial transport function and were used to model several diseases, including BK virus, Wilms tumor, and cystic fibrosis, showing the great potential of this culture system for disease modeling and the possibility to use it for drug screening (Schutgens et al. 2019).

A lack of vascularization could potentially be overcome by the use of a 3D-print chip that combines hPSC-derived kidney organoids co-cultured with glomerular microvascular endothelial cells (GMECs) in a gelatin-fibrin ECM, as recently reported (Homan et al. 2016, 2019). The researchers showed an improved maturation of the kidney organoids when cultured under flow and in the presence of vascularization. Later, the same microfluidic platform was used to study active reabsorption of solutes between proximal tubule epithelial cells and vascular epithelium, and for the study of hyperglycemic conditions.

As mentioned before, the kidney also interacts with and reacts on remote organs. The liver and the kidney are two very complex organs that together lead to the metabolism and excretion of drugs, respectively. To predict biotransformation (liver) and elimination (kidney) in humans is a rather difficult task to achieve using normal 2D cultures (Chang et al. 2016); however, the combination of these two complex organs in an organ-on-a-chip platform made it possible to study the toxic effects of aristolochic acid I, a well-known nephrotoxicant that requires first hepatic bioactivation (Chang et al. 2017). Table 3 summarizes the different in vitro models discussed to study drug-induced nephrotoxicity. Together, the findings suggest that the development and use of advanced in vitro kidney models are important improvements in renal drug safety assessment.

Perspectives in in vitro models’ development

Renal clearance is an important route of drug elimination from the bloodstream, mainly facilitated by the proximal tubule, which renders proximal tubule epithelial cells prone to drug-induced kidney injury. Mimicking the in vivo environment by including extracellular matrix (ECM) components, three-dimensional (3D) architectural features, a heterogeneous cellular composition and incorporating fluid shear stress in an in vitro kidney model could improve prediction of injury after drug exposures. These features need to be taken into consideration when trying to develop new in vitro models. The complex renal ECM, recently reviewed in (van Genderen et al. 2018), is in constant remodeling, especially in the transition of healthy to disease state, such as fibrosis. As fibrosis affect the different compartments of the kidney, a comprehensive analysis of the renal ECM is crucial to study the pathophysiology of the disease and its specific biomarkers (Bülow and Boor 2019). As stated before, shear stress triggers mechanosensitive pathways via microvilli, cilia, and the glycocalyx. Understanding how these structures coordinate with each other in response to flow will broaden our knowledge and help identify new molecular targets of diseases (Raghavan and Weisz 2016). Combining these features in a 3D model that includes tubule curvature (Yu et al. 2018) will allow for a better cell polarization and enhanced expression of cell markers.

Currently, in pre-clinical safety assessment studies, only a limited number of drug candidates (2–8%) are being rejected because of nephrotoxicity (Cook et al. 2014; Guengerich 2011). A survey among pharmaceutical companies showed that the majority of drug candidates displaying nephrotoxicity in clinical trials did not show nephrotoxicity in pre-clinical trials (Troth et al. 2019). It is thus apparent that the currently used strategies to predict drug-induced injury warrant strong improvements. Immortalized cell lines, like ciPTEC, represent a steady and reproducible cell source for in vitro models, but are derived from one single donor and show significant changes in cell function and morphology compared to primary cells (Astashkina et al. 2012). Baseline levels of injury marker KIM-1 were 20-fold higher in immortalized cells compared to primary cells (Sakolish et al. 2018). In addition, immortalized cell lines often show chromosomal instability, as demonstrated for ciPTEC-OAT1 without affecting cell function or posing a tumorigenic risk (Mihajlovic et al. 2019), and represent a homogenous population instead of a genetic diverse population. Therefore, new sources for kidney cells emerged in the past decade. Stem cell-derived tubular cells can be obtained from multiple donors and may have potential for studying nephrotoxicity in a heterogeneous population (Wnorowski et al. 2018). Well-defined protocols to establish kidney organoids of renal tubular epithelial cells from induced pluripotent stem cells (iPSCs) derived from fibroblasts are now available (Czerniecki et al. 2018; Freedman et al. 2015; Kaminski Michael et al. 2016; Morizane et al. 2015; Takasato et al. 2015). In these cultures, typical proximal tubule cell characteristics have been demonstrated, such as albumin uptake, expression of tight junction proteins, expression of OAT1, microvilli, and apical and basolateral membrane polarization. In addition, cytotoxicity was demonstrated using cisplatin (Czerniecki et al. 2018; Freedman et al. 2015; Kaminski Michael et al. 2016; Morizane et al. 2015; Takasato et al. 2015), gentamicin (Freedman et al. 2015; Kaminski Michael et al. 2016; Morizane et al. 2015), tacrolimus (Kaminski Michael et al. 2016), and adriamycin (Kumar et al. 2019). As earlier stated, kidney tubuloids grown from adult stem cells (ASCs) are another promising approach as they allow for long-term culturing and better maturation without losing chromosomal stability (Schutgens et al. 2019).

To model kidney diseases, direct pathogen exposure and genome editing have been applied, depending on the cause of disease. Effects of Shiga toxin 2, a cytotoxic protein causing hemolytic-uremic syndrome (HUS), were studied in a 3D model of renal cortical epithelial cells (DesRochers et al. 2015). And polycystic kidney disease was studied via CRISPR-Cas9 genome editing of PC-1 and -2 in iPSC-derived kidney organoids (Czerniecki et al. 2018; Freedman et al. 2015). Personalized medicine allows for studying disease progression and testing treatment options in a tailor-made fashion via obtaining tissue from kidney disease patients. ASCs-derived tubuloids from Wilms tumors elucidated an important role for SIX2, a kidney development marker (Kobayashi et al. 2008; Schutgens et al. 2019). Furthermore, tubuloids obtained via urine from cystic fibrosis patients were used to assess treatment efficacy and circumvented the use of an invasive method to obtain patient material (Schutgens et al. 2019). Furthermore, the dynamic process of kidney stone formation was studied in HK-2 cells cultured in a microfluidic device, which allowed real-time monitoring of calcium phosphate deposition in the lumen (Wei et al. 2012).

Improving predictability of in vitro models fits also in the scope of the 3Rs (replacement, reduction, refinement) of animal experiments. This could reduce costs of the pre-clinical and clinical phases of drug development by filtering out the harmful compounds. However, more importantly, it also meets the societal demands to reduce the number of animals in drug development. Drug regulatory authorities, such as FDA and EMA, support the use of physiologically based pharmacokinetic (PBPK) modeling as a tool to facilitate the process of drug development. In vitro-to-in vivo extrapolation (IVIVE) can be coupled with PBPK modeling as a way to predict the in vivo pharmacokinetic characteristics of a new drug based on in vitro studies. In vitro studies can provide information regarding drug–enzyme and drug–transporter interactions. However, the full understanding of the absorption, distribution, metabolism, and excretion (ADME) processes is not feasible. By extrapolating complex scenarios observed in vitro while having in mind that intrinsic and extrinsic factors can alter the kinetic values, one can identify optimal dosing regimens for individual patients (Rostami-Hodjegan 2012; Zhao et al. 2011; van der Made et al. 2019).

Conclusions

Nephrotoxicity is associated with significant mortality and morbidity. Undoubtedly, drug-induced nephrotoxicity is a major cause of renal impairments and a potential impediment to the research and development of drugs, requiring more reliable and early diagnosis to avoid potentially fatal chronic conditions. To date, there is no ideal kidney-based in vitro model for the study of nephrotoxicity; however, we are moving towards more advanced in vitro culture systems that offer great promise for the assessment of drug toxicity. These new models include several characteristics that are important for the successful toxicologic read-out of drug candidates, including 3D architectural features, ECM components, fluid flow, and multiple cell types combined. Despite the promising advances of these models, appropriate toxicity end-points and sensitive translational biomarkers are yet to be identified. Current efforts remain as “bench-work” and do not reach the “bed-side”. Therefore, there is a pressing need to systematically combine in vitro, in vivo, and clinical inspections to develop a panel of safety biomarkers that can effectively and reliably diagnose and monitor renal function, damage, and recovery.

Notes

Acknowledgements

This study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant agreement no. 813839.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest with the contents of this article.

References

  1. Alinejad S, Ghaemi K, Abdollahi M, Mehrpour O (2016) Nephrotoxicity of methadone: a systematic review. Springerplus 5(1):2087.  https://doi.org/10.1186/s40064-016-3757-1 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Anders MW (1980) Metabolism of drugs by the kidney. Kidney Int 18:636–647.  https://doi.org/10.1038/KI.1980.181 CrossRefPubMedGoogle Scholar
  3. Andreucci M, Faga T, Pisani A, Perticone M, Michael A (2017) The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. Eur J Intern Med 39:1–8.  https://doi.org/10.1016/j.ejim.2016.12.001 CrossRefPubMedGoogle Scholar
  4. Arakawa H, Washio I, Matsuoka N et al (2017) Usefulness of kidney slices for functional analysis of apical reabsorptive transporters. Sci Rep 7:12814.  https://doi.org/10.1038/s41598-017-12828-z CrossRefPubMedPubMedCentralGoogle Scholar
  5. Aschauer L, Limonciel A, Wilmes A et al (2015) Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: a transcriptomic study. Toxicol In Vitro 30:106–116.  https://doi.org/10.1016/J.TIV.2014.10.005 CrossRefPubMedGoogle Scholar
  6. Astashkina A, Mann B, Grainger DW (2012) A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther 134(1):82–106.  https://doi.org/10.1016/j.pharmthera.2012.01.001 CrossRefPubMedGoogle Scholar
  7. Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH (2015) Lithium nephrotoxicity. Int J. Bipolar Disord 3(1):28.  https://doi.org/10.1186/s40345-015-0028-y CrossRefGoogle Scholar
  8. Bajaj P, Chowdhury SK, Yucha R, Kelly EJ, Xiao G (2018) Emerging kidney models to investigate metabolism, transport, and toxicity of drugs and xenobiotics (1521-009X (Electronic))CrossRefGoogle Scholar
  9. Barnett LMA, Cummings BS (2018) Nephrotoxicity and renal pathophysiology: a contemporary perspective. Toxicol Sci 164:379–390.  https://doi.org/10.1093/toxsci/kfy159 CrossRefPubMedGoogle Scholar
  10. Barré-Sinoussi F, Montagutelli X (2015) Animal models are essential to biological research: issues and perspectives. Future Sci OA 1(4):FSO63.  https://doi.org/10.4155/fso.15.63 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Basile DP, Anderson MD, Sutton TA (2012) Pathophysiology of acute kidney injury. Compr Physiol 2:1303–1353.  https://doi.org/10.1002/cphy.c110041 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Basu RK, Wheeler DS (2013) Kidney-lung cross-talk and acute kidney injury. Pediatr Nephrol (Berlin, Germany) 28:2239–2248.  https://doi.org/10.1007/s00467-012-2386-3 CrossRefGoogle Scholar
  13. Bello-Reuss E, Reuss L (1983) Homeostatic and excretory functions of the kidney the kidney and body fluids in health and disease. Springer, Boston, pp 35–63CrossRefGoogle Scholar
  14. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA (2013) Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ Can Med Assoc J journal de l’Association medicale canadienne 185(10):E475–E482.  https://doi.org/10.1503/cmaj.121730 CrossRefGoogle Scholar
  15. Bolignano D, Donato V, Coppolino G et al (2008) Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 52(3):595–605.  https://doi.org/10.1053/j.ajkd.2008.01.020 CrossRefPubMedGoogle Scholar
  16. Bolisetty S, Agarwal A (2011) Urine albumin as a biomarker in acute kidney injury. Am J Physiol Renal Physiol 300(3):F626–F627.  https://doi.org/10.1152/ajprenal.00004.2011 CrossRefPubMedPubMedCentralGoogle Scholar
  17. Breda PC, Wiech T, Meyer-Schwesinger C et al (2019) Renal proximal tubular epithelial cells exert immunomodulatory function by driving inflammatory CD4+ T cell responses. Am J Physiol Renal Physiol 317(1):F77–F89.  https://doi.org/10.1152/ajprenal.00427.2018 CrossRefPubMedGoogle Scholar
  18. Brodsky SV (2014) Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney Res Clin Pract 33(4):174–180.  https://doi.org/10.1016/j.krcp.2014.11.001 CrossRefPubMedPubMedCentralGoogle Scholar
  19. Brown CD, Sayer R, Windass AS et al (2008a) Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233(3):428–438CrossRefGoogle Scholar
  20. Brown CDA, Sayer R, Windass AS et al (2008b) Characterisation of human tubular cell monolayers as a model of proximal tubular xenobiotic handling. Toxicol Appl Pharmacol 233:428–438.  https://doi.org/10.1016/J.TAAP.2008.09.018 CrossRefPubMedGoogle Scholar
  21. Bülow RD, Boor P (2019) Extracellular matrix in kidney fibrosis: more than just a scaffold. J Histochem Cytochem.  https://doi.org/10.1369/0022155419849388 CrossRefPubMedGoogle Scholar
  22. Busauschina A, Schnuelle P, van der Woude FJ (2004) Cyclosporine nephrotoxicity. Transpl Proc 36(2 Suppl):229s–233s.  https://doi.org/10.1016/j.transproceed.2004.01.021 CrossRefGoogle Scholar
  23. Cai Z, Xin J, Pollock DM, Pollock JS (2000) Shear stress-mediated NO production in inner medullary collecting duct cells. Am J Physiol Renal Physiol 279(2):F270–F274.  https://doi.org/10.1152/ajprenal.2000.279.2.F270 CrossRefPubMedGoogle Scholar
  24. Chang SY, Weber EJ, Ness KV, Eaton DL, Kelly EJ (2016) Liver and kidney on chips: microphysiological models to understand transporter function. Clin Pharmacol Ther 100(5):464–478.  https://doi.org/10.1002/cpt.436 CrossRefPubMedPubMedCentralGoogle Scholar
  25. Chang S-Y, Weber EJ, Sidorenko VS et al (2017) Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight 2(22):e95978.  https://doi.org/10.1172/jci.insight.95978 CrossRefPubMedCentralGoogle Scholar
  26. Chapman AB, Devuyst O, Eckardt K-U et al (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88(1):17–27.  https://doi.org/10.1038/ki.2015.59 CrossRefPubMedPubMedCentralGoogle Scholar
  27. Chevtchik NV, Mihajlovic M, Fedecostante M et al (2018) A bioartificial kidney device with polarized secretion of immune modulators. J Tissue Eng Regen Med 12:1670–1678.  https://doi.org/10.1002/term.2694 CrossRefPubMedGoogle Scholar
  28. Choudhury D, Ahmed Z (2006) Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2(2):80–91.  https://doi.org/10.1038/ncpneph0076 CrossRefPubMedGoogle Scholar
  29. Coco TJ, Klasner AE (2004) Drug-induced rhabdomyolysis. Curr Opin Pediatr 16(2):206–210CrossRefGoogle Scholar
  30. Cook D, Brown D, Alexander R et al (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discovery 13:419.  https://doi.org/10.1038/nrd4309 CrossRefPubMedGoogle Scholar
  31. Czerniecki SM, Cruz NM, Harder JL et al (2018) High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping. Cell Stem Cell 22(6):929.e4–940.e4.  https://doi.org/10.1016/j.stem.2018.04.022 CrossRefGoogle Scholar
  32. de Chuva de Sousa Lopes SM (2019) Accelerating maturation of kidney organoids. Nat Mater 18(4):303–304.  https://doi.org/10.1038/s41563-019-0326-3 CrossRefPubMedGoogle Scholar
  33. De Kanter R, Olinga P, De Jager MH, Merema MT, Meijer DK, Groothius GM (1999) Organ slices as an in vitro test system for drug metabolism in human liver, lung and kidney. Toxicol In Vitro 13(4–5):737–744CrossRefGoogle Scholar
  34. Deray G (2002) Amphotericin B nephrotoxicity. The Journal of antimicrobial chemotherapy 49(Suppl 1):37–41.  https://doi.org/10.1093/jac/49.suppl_1.37 CrossRefPubMedGoogle Scholar
  35. Desrochers T, Suter-Dick L, Roth A, Kaplan D (2013) Bioengineered 3D human kidney tissue, a platform for the determination of nephrotoxicity. PLoS One 8:e59219.  https://doi.org/10.1371/annotation/fb32f1b8-7397-40be-bbf9-b80e67763043 CrossRefPubMedPubMedCentralGoogle Scholar
  36. DesRochers TM, Kimmerling EP, Jandhyala DM et al (2015) Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue. Infect Immun 83(1):28–38.  https://doi.org/10.1128/IAI.02143-14 CrossRefPubMedGoogle Scholar
  37. Dieterle F, Perentes E, Cordier A et al (2010a) Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol 28(5):463–469.  https://doi.org/10.1038/nbt.1622 CrossRefPubMedGoogle Scholar
  38. Dieterle F, Sistare F, Goodsaid F et al (2010b) Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28(5):455–462.  https://doi.org/10.1038/nbt.1625 CrossRefGoogle Scholar
  39. Dixit M, Doan T, Kirschner R, Dixit N (2010) significant acute kidney injury due to non-steroidal anti-inflammatory drugs: inpatient setting. Pharmaceuticals (Basel, Switzerland) 3:1279–1285.  https://doi.org/10.3390/ph3041279 CrossRefGoogle Scholar
  40. du Cheyron D, Daubin C, Poggioli J et al (2003) Urinary measurement of Na+/H+ exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am J Kidney Dis 42(3):497–506CrossRefGoogle Scholar
  41. Eddy AA, Fogo AB (2006) Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 17(11):2999–3012.  https://doi.org/10.1681/asn.2006050503 CrossRefPubMedGoogle Scholar
  42. Eirin A, Lerman A, Lerman LO (2017) The emerging role of mitochondrial targeting in kidney disease. Handb Exp Pharmacol 240:229–250.  https://doi.org/10.1007/164_2016_6 CrossRefPubMedPubMedCentralGoogle Scholar
  43. Ejaz P, Bhojani K, Joshi VR (2004) NSAIDs and kidney. J Assoc Physicians India 52:632–640PubMedGoogle Scholar
  44. Eshbach ML, Weisz OA (2017) Receptor-mediated endocytosis in the proximal tubule. Annu Rev Physiol 79(1):425–448.  https://doi.org/10.1146/annurev-physiol-022516-034234 CrossRefPubMedGoogle Scholar
  45. Fedecostante M, Onciu OG, Westphal KGC, Masereeuw R (2017) Towards a bioengineered kidney: recellularization strategies for decellularized native kidney scaffolds. Int J Artif Org 40:150–158.  https://doi.org/10.5301/ijao.5000564 CrossRefGoogle Scholar
  46. Fedecostante M, Westphal KGC, Buono MF et al (2018) recellularized native kidney scaffolds as a novel tool in nephrotoxicity screening. Drug Metab Dispos Biol Fate Chem 46(9):1338–1350.  https://doi.org/10.1124/dmd.118.080721 CrossRefPubMedGoogle Scholar
  47. Feher J (2017) Tubular Reabsorption and Secretion. Quant Hum Physiol.  https://doi.org/10.1016/b978-0-12-800883-6.00072-0 CrossRefGoogle Scholar
  48. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB et al (2011) Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat 2011:354908.  https://doi.org/10.1155/2011/354908 CrossRefPubMedPubMedCentralGoogle Scholar
  49. Frazier KS, Obert LA (2018) Drug-induced glomerulonephritis: the spectre of biotherapeutic and antisense oligonucleotide immune activation in the kidney. Toxicol Pathol 46(8):904–917.  https://doi.org/10.1177/0192623318789399 CrossRefPubMedGoogle Scholar
  50. Freedman BS, Brooks CR, Lam AQ et al (2015) Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. Nat Commun 6:8715.  https://doi.org/10.1038/ncomms9715 CrossRefPubMedPubMedCentralGoogle Scholar
  51. Frochot V, Bazin D, Letavernier E, Jouanneau C, Haymann J-P, Daudon M (2016) Nephrotoxicity induced by drugs: the case of foscarnet and atazanavir—a SEM and μFTIR investigation. C R Chim 19(11):1565–1572.  https://doi.org/10.1016/j.crci.2016.08.007 CrossRefGoogle Scholar
  52. Georgiev T, Iliev R, Mihailova S et al (2011) The isolated perfused kidney models—certain aspects. Trakia J Sci 9(3):82–87Google Scholar
  53. Ghane Shahrbaf F, Assadi F (2015) Drug-induced renal disorders. J Renal Inj Prev 4(3):57–60.  https://doi.org/10.12861/jrip.2015.12 CrossRefPubMedPubMedCentralGoogle Scholar
  54. Giacomini KM, Huang SM, Tweedie DJ et al (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215–236CrossRefGoogle Scholar
  55. Guengerich FP (2011) Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 26(1):3–14CrossRefGoogle Scholar
  56. Han WK, Waikar SS, Johnson A et al (2008) Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 73(7):863–869.  https://doi.org/10.1038/sj.ki.5002715 CrossRefPubMedGoogle Scholar
  57. Han C, Lee Y-K, Park HC et al (2019) Serum alkaline phosphatase and γ-glutamyl transferase in acute pyelonephritis. Kidney Res Clin Pract 38(2):205–211.  https://doi.org/10.23876/j.krcp.18.0074 CrossRefPubMedPubMedCentralGoogle Scholar
  58. Hanemann AL, Liborio AB, Daher EF et al (2013) Monocyte chemotactic protein-1 (MCP-1) in patients with chronic schistosomiasis mansoni: evidences of subclinical renal inflammation. PLoS One 8(11):e80421.  https://doi.org/10.1371/journal.pone.0080421 CrossRefPubMedPubMedCentralGoogle Scholar
  59. Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M (2015) Atazanavir nephrotoxicity. Clin Kidney J 8(2):137–142.  https://doi.org/10.1093/ckj/sfv015 CrossRefPubMedPubMedCentralGoogle Scholar
  60. Haussler MR, Whitfield GK, Haussler CA et al (2016) 1,25-Dihydroxyvitamin D and klotho: a tale of two renal hormones coming of age. Vitam Horm 100:165–230.  https://doi.org/10.1016/BS.VH.2015.11.005 CrossRefPubMedGoogle Scholar
  61. Hayashi H, Sato W, Kosugi T et al (2017) Efficacy of urinary midkine as a biomarker in patients with acute kidney injury. Clin Exp Nephrol 21(4):597–607.  https://doi.org/10.1007/s10157-016-1318-0 CrossRefPubMedGoogle Scholar
  62. Hidaka S, Kranzlin B, Gretz N, Witzgall R (2002) Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res 310(3):289–296.  https://doi.org/10.1007/s00441-002-0629-5 CrossRefPubMedGoogle Scholar
  63. Hitti WA, Anderson J (2005) Cholesterol emboli-induced renal failure and gastric ulcer after thrombolytic therapy. South Med J 98(2):235–237.  https://doi.org/10.1097/01.Smj.0000152754.12363.45 CrossRefPubMedGoogle Scholar
  64. Holechek MJ (2003) Glomerular filtration: an overview. Nephrol Nurs J J Am Nephrol Nurs Assoc 30:285–290 (quiz 291–2) Google Scholar
  65. Homan KA, Kolesky DB, Skylar-Scott MA et al (2016) Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Sci Rep.  https://doi.org/10.1038/srep34845 CrossRefPubMedPubMedCentralGoogle Scholar
  66. Homan KA, Gupta N, Kroll KT et al (2019) Flow-enhanced vascularization and maturation of kidney organoids in vitro. Nat Methods 16(3):255–262.  https://doi.org/10.1038/s41592-019-0325-y CrossRefPubMedPubMedCentralGoogle Scholar
  67. Htike NL, Santoro J, Gilbert B, Elfenbein IB, Teehan G (2012) Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol 16(2):320–324.  https://doi.org/10.1007/s10157-011-0559-1 CrossRefPubMedGoogle Scholar
  68. Izzedine H, Launay-Vacher V, Deray G (2005) Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 45(5):804–817CrossRefGoogle Scholar
  69. Jafari A, Khalili H, Dashti-Khavidaki S (2014) Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol 70(9):1029–1040.  https://doi.org/10.1007/s00228-014-1712-z CrossRefPubMedGoogle Scholar
  70. Jang KJ, Mehr AP, Hamilton GA et al (2013) Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integr Biol (United Kingdom).  https://doi.org/10.1039/c3ib40049b CrossRefGoogle Scholar
  71. Jansen J, Schophuizen CMS, Wilmer MJ et al (2014) A morphological and functional comparison of proximal tubule cell lines established from human urine and kidney tissue. Exp Cell Res 323(1):87–99.  https://doi.org/10.1016/j.yexcr.2014.02.011 CrossRefPubMedGoogle Scholar
  72. Jansen J, De Napoli IE, Fedecostante M et al (2015) Human proximal tubule epithelial cells cultured on hollow fibers: living membranes that actively transport organic cations. Sci Rep 5:16702.  https://doi.org/10.1038/srep16702 CrossRefPubMedPubMedCentralGoogle Scholar
  73. Jansen J, Fedecostante M, Wilmer MJ et al (2016a) Bioengineered kidney tubules efficiently excrete uremic toxins. Sci Rep 6:1–12.  https://doi.org/10.1038/srep26715 CrossRefGoogle Scholar
  74. Jansen J, Fedecostante M, Wilmer MJ et al (2016b) Bioengineered kidney tubules efficiently excrete uremic toxins. Sci Rep 6:26715.  https://doi.org/10.1038/srep26715 CrossRefPubMedPubMedCentralGoogle Scholar
  75. Jansen J, Jansen K, Neven E et al (2019) Remote sensing and signaling in kidney proximal tubules stimulates gut microbiome-derived organic anion secretion. Proc Natl Acad Sci USA.  https://doi.org/10.1073/pnas.1821809116 CrossRefPubMedGoogle Scholar
  76. Jenkinson SE, Chung GW, van Loon E, Bakar NS, Dalzell AM, Brown CD (2012a) The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflugers Arch 464(6):601–611CrossRefGoogle Scholar
  77. Jenkinson SE, Chung GW, van Loon E, Bakar NS, Dalzell AM, Brown CDA (2012b) The limitations of renal epithelial cell line HK-2 as a model of drug transporter expression and function in the proximal tubule. Pflügers Arch Eur J Physiol 464:601–611.  https://doi.org/10.1007/s00424-012-1163-2 CrossRefGoogle Scholar
  78. Jia HM, Huang LF, Zheng Y, Li WX (2017) Diagnostic value of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor binding protein 7 for acute kidney injury: a meta-analysis. Crit Care (London, England) 21(1):77.  https://doi.org/10.1186/s13054-017-1660-y CrossRefGoogle Scholar
  79. Kakoki M, Smithies O (2009) The kallikrein–kinin system in health and in diseases of the kidney. Kidney Int 75:1019.  https://doi.org/10.1038/KI.2008.647 CrossRefPubMedPubMedCentralGoogle Scholar
  80. Kalyesubula R, Perazella MA (2011) Nephrotoxicity of HAART. AIDS Res Treat 2011:562790.  https://doi.org/10.1155/2011/562790 CrossRefPubMedPubMedCentralGoogle Scholar
  81. Kamijo A, Sugaya T, Hikawa A et al (2006) Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284(1–2):175–182.  https://doi.org/10.1007/s11010-005-9047-9 CrossRefPubMedGoogle Scholar
  82. Kaminski Michael M, Tosic J, Kresbach C et al (2016) Direct reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors. Nat Cell Biol 18:1269.  https://doi.org/10.1038/ncb3437 CrossRefPubMedGoogle Scholar
  83. Kandasamy K, Chuah JKC, Su R et al (2015) Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods. Sci Rep 5:12337.  https://doi.org/10.1038/srep12337 CrossRefPubMedPubMedCentralGoogle Scholar
  84. Kazancioğlu R (2013) Risk factors for chronic kidney disease: an update. Kidney Int Suppl 3:368.  https://doi.org/10.1038/KISUP.2013.79 CrossRefGoogle Scholar
  85. Kim J-H, Hwang K-H, Park K-S, Kong ID, Cha S-K (2015) Biological role of anti-aging protein Klotho. J Lifestyle Med 5:1–6.  https://doi.org/10.15280/jlm.2015.5.1.1 CrossRefPubMedPubMedCentralGoogle Scholar
  86. Kipp R, Kellerman PS (2009) Chronic kidney disease. Pathophysiol Kidney Dis Hypertens.  https://doi.org/10.1016/b978-1-4160-4391-1.50018-7 CrossRefGoogle Scholar
  87. Kobayashi A, Valerius MT, Mugford JW et al (2008) Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. Cell Stem Cell 3(2):169–181.  https://doi.org/10.1016/j.stem.2008.05.020 CrossRefPubMedPubMedCentralGoogle Scholar
  88. Koeppen BM, Stanton BA (2013) Renal physiology, 5th edn. Elsevier. ISBN: 978-0-323-08691-2Google Scholar
  89. Kowalkowski K, Klapczynski M, Blomme E, Buck W, Liguori M (2017) Evaluating in vitro canine kidney slices as a renal toxicity model using nephrotoxic agents cisplatin and cadmium chloride. FASEB J 31:819.8.  https://doi.org/10.1096/fasebj.31.1_supplement.819.8 CrossRefGoogle Scholar
  90. Kumar R, Tebben PJ, Thompson JR (2012) Vitamin D and the kidney. Arch Biochem Biophys 523:77–86.  https://doi.org/10.1016/j.abb.2012.03.003 CrossRefPubMedPubMedCentralGoogle Scholar
  91. Kumar SV, Er PX, Lawlor KT et al (2019) Kidney micro-organoids in suspension culture as a scalable source of human pluripotent stem cell-derived kidney cells. Development 146(5):dev172361.  https://doi.org/10.1242/dev.172361 CrossRefPubMedPubMedCentralGoogle Scholar
  92. Lam AQ, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre JV (2014) Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. J Am Soc Nephrol JASN 25:1211–1225.  https://doi.org/10.1681/ASN.2013080831 CrossRefPubMedGoogle Scholar
  93. Lameire N (2014) Nephrotoxicity of recent anti-cancer agents. Clin Kidney J 7(1):11–22.  https://doi.org/10.1093/ckj/sft135 CrossRefPubMedGoogle Scholar
  94. Lameire N, Van Biesen W, Vanholder R (2005) Acute renal failure. Lancet (London, England) 365(9457):417–430.  https://doi.org/10.1016/s0140-6736(05)17831-3 CrossRefGoogle Scholar
  95. Lane K, Dixon JJ, Macphee IAM, Philips BJ (2013) Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? Nephrol Dial Transplant 28:1634–1647.  https://doi.org/10.1093/ndt/gft091 CrossRefPubMedGoogle Scholar
  96. Lee J, Kim S (2018) Kidney-on-a-chip: a new technology for predicting drug efficacy, interactions, and drug-induced nephrotoxicity. Curr Drug Metab 19:577–583.  https://doi.org/10.2174/1389200219666180309101844 CrossRefPubMedGoogle Scholar
  97. Lee EJ, Song SA, Mun HW, Yoo KH et al (2014) Blockade of interleukin-8 receptor signalling inhibits cyst development in vitro, via suppression of cell proliferation in autosomal polycystic kidney disease (1440–1797 (Electronic))Google Scholar
  98. Levy JB, Pusey CD (2000) Nephrotoxicity of intravenous immunoglobulin. QJM Mon J Assoc Physicians 93(11):751–755.  https://doi.org/10.1093/qjmed/93.11.751 CrossRefGoogle Scholar
  99. Liang Y, Li S, Chen L (2015a) The physiological role of drug transporters. Protein Cell 6:334.  https://doi.org/10.1007/S13238-015-0148-2 CrossRefPubMedPubMedCentralGoogle Scholar
  100. Liang Y, Zhang J, Zhou Y, Xing G, Zhao G, Liu Z (2015b) Proliferation and cytokine production of human mesangial cells stimulated by secretory IgA isolated from patients with IgA nephropathy. Cell Physiol Biochem 36(5):1793–1808.  https://doi.org/10.1159/000430151 CrossRefPubMedGoogle Scholar
  101. Liu Y, Yin Y, Liu XZ et al (2015) Retrospective analysis of vancomycin nephrotoxicity in elderly Chinese patients. Pharmacology 95(5–6):279–284.  https://doi.org/10.1159/000381783 CrossRefPubMedGoogle Scholar
  102. Liu X, Guan Y, Xu S et al (2016) Early predictors of acute kidney injury: a narrative review. Kidney Blood Press Res 41(5):680–700.  https://doi.org/10.1159/000447937 CrossRefPubMedGoogle Scholar
  103. Liu Y, Liu B, Liu Y et al (2019) MicroRNA expression profile by next-generation sequencing in a novel rat model of contrast-induced acute kidney injury. Ann Transl Med 7(8):178.  https://doi.org/10.21037/atm.2019.04.44 CrossRefPubMedPubMedCentralGoogle Scholar
  104. Lopez MLSS, Gomez RA (2010) The renin phenotype: roles and regulation in the kidney. Curr Opin Nephrol Hypertens 19:366–371.  https://doi.org/10.1097/MNH.0b013e32833aff32 CrossRefPubMedGoogle Scholar
  105. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ (2011) New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 79(1):33–45.  https://doi.org/10.1038/ki.2010.337 CrossRefPubMedGoogle Scholar
  106. Lote CJ (2012) Essential anatomy of the kidney principles of renal physiology. Springer, New York, pp 21–32CrossRefGoogle Scholar
  107. Lucas GNC, Leitão ACC, Alencar RL, Xavier RMF, Daher EDF, Silva Junior GBD (2019) Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory drugs. J Braz J Nephrol 41:124–130Google Scholar
  108. Macedo E, Mehta RL (2009) Prerenal Failure: from Old Concepts to New Paradigms. Current opinion in critical care 15:467.  https://doi.org/10.1097/MCC.0B013E328332F6E3 CrossRefPubMedPubMedCentralGoogle Scholar
  109. Mae S-I, Shono A, Shiota F et al (2013) Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun 4:1367.  https://doi.org/10.1038/ncomms2378 CrossRefPubMedPubMedCentralGoogle Scholar
  110. Makris K, Spanou L (2016) Acute kidney injury: definition, pathophysiology and clinical phenotypes. Clin Biochem Rev 37:85PubMedPubMedCentralGoogle Scholar
  111. Małyszko J, Kozłowska K, Kozłowski L, Małyszko J (2016) Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant 32(6):924–936.  https://doi.org/10.1093/ndt/gfw338 CrossRefGoogle Scholar
  112. Manabe K, Kamihata H, Motohiro M, Senoo T, Yoshida S, Iwasaka T (2012) Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury. Eur J Clin Investig 42(5):557–563.  https://doi.org/10.1111/j.1365-2362.2011.02620.x CrossRefGoogle Scholar
  113. Markowitz GS, Perazella MA (2005) Drug-induced renal failure: a focus on tubulointerstitial disease. Clin Chim Acta Int J Clin Chem 351(1–2):31–47.  https://doi.org/10.1016/j.cccn.2004.09.005 CrossRefGoogle Scholar
  114. Markowitz GS, Fine PL, Stack JI et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64(1):281–289.  https://doi.org/10.1046/j.1523-1755.2003.00071.x CrossRefPubMedGoogle Scholar
  115. Marti H-P, Frey FJ (2005) Nephrotoxicity of rapamycin: an emerging problem in clinical medicine. Nephrol Dial Transplant 20(1):13–15.  https://doi.org/10.1093/ndt/gfh639 CrossRefPubMedGoogle Scholar
  116. McCann B, Hunter R, McCann J (2002) Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation. Emerg Med J 19(3):264.  https://doi.org/10.1136/emj.19.3.264 CrossRefPubMedPubMedCentralGoogle Scholar
  117. Medina PJ, Sipols JM, George JN (2001) Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 8(5):286–293CrossRefGoogle Scholar
  118. Mihajlovic M, Fedecostante M, Oost MJ et al (2017) Role of vitamin D in maintaining renal epithelial barrier function in uremic conditions. Int J Mol Sci 18(12):2531.  https://doi.org/10.3390/ijms18122531 CrossRefPubMedCentralGoogle Scholar
  119. Mihajlovic M, Hariri S, Westphal KCG et al (2019) Safety evaluation of conditionally immortalized cells for renal replacement therapy. Oncotarget 10(51):5332–5348.  https://doi.org/10.18632/oncotarget.27152 CrossRefPubMedPubMedCentralGoogle Scholar
  120. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel) 2(11):2490–2518.  https://doi.org/10.3390/toxins2112490 CrossRefGoogle Scholar
  121. Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV (2015) Nephron organoids derived from human pluripotent stem cells model kidney development and injury. Nat Biotechnol 33:1193.  https://doi.org/10.1038/nbt.3392 CrossRefPubMedPubMedCentralGoogle Scholar
  122. Murphy RA, Stafford RM, Petrasovits BA, Boone MA, Valentovic MA (2017) Establishment of HK-2 cells as a relevant model to study tenofovir-induced cytotoxicity. Int J Mol Sci.  https://doi.org/10.3390/ijms18030531 CrossRefPubMedPubMedCentralGoogle Scholar
  123. Naughton CA (2008a) Drug-induced nephrotoxicity. Am Fam Physician 78(6):743–750PubMedGoogle Scholar
  124. Naughton CA (2008b) Drug-induced nephrotoxicity. Am Fam Physician 78:743–750PubMedGoogle Scholar
  125. Navis G, Faber HJ, de Zeeuw D, de Jong PE (1996) ACE inhibitors and the kidney. Drug Saf 15:200–211.  https://doi.org/10.2165/00002018-199615030-00005 CrossRefPubMedGoogle Scholar
  126. Nieskens TTG, Peters JGP, Schreurs MJ et al (2016) A human renal proximal tubule cell line with stable organic anion transporter 1 and 3 expression predictive for antiviral-induced toxicity. AAPS J 18:465–475.  https://doi.org/10.1208/s12248-016-9871-8 CrossRefPubMedPubMedCentralGoogle Scholar
  127. Nigam SK (2018) The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease. Annu Rev Pharmacol Toxicol 58(1):663–687.  https://doi.org/10.1146/annurev-pharmtox-010617-052713 CrossRefPubMedPubMedCentralGoogle Scholar
  128. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V (2015) Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clin J Am Soc Nephrol 10(11):2039–2049.  https://doi.org/10.2215/cjn.02440314 CrossRefPubMedPubMedCentralGoogle Scholar
  129. Nissim I, Horyn O, Daikhin Y et al (2006) Ifosfamide-induced nephrotoxicity: mechanism and prevention. Can Res 66(15):7824–7831.  https://doi.org/10.1158/0008-5472.Can-06-1043 CrossRefGoogle Scholar
  130. Ohana YH, Liron T, Prutchi-Sagiv S, Mittelman M, Souroujon MC, Neumann D (2013) Erythropoietin. In: Handbook of biologically active peptides, pp 1619–1626.  https://doi.org/10.1016/b978-0-12-385095-9.00221-9 CrossRefGoogle Scholar
  131. Olyaei AJ, de Mattos AM, Bennett WM (2001) Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 7(6):384–389CrossRefGoogle Scholar
  132. Onopiuk A, Tokarzewicz A, Gorodkiewicz E (2015) Cystatin C: a kidney function biomarker. Adv Clin Chem 68:57–69.  https://doi.org/10.1016/bs.acc.2014.11.007 CrossRefPubMedGoogle Scholar
  133. Ozer JS, Dieterle F, Troth S et al (2010) A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol 28(5):486–494.  https://doi.org/10.1038/nbt.1627 CrossRefPubMedGoogle Scholar
  134. Pahl MV, Vaziri ND, Yuan J, Adler SG (2010) Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol CJASN 5(1):56–61.  https://doi.org/10.2215/cjn.03390509 CrossRefPubMedGoogle Scholar
  135. Palmer BF (2002) Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347(16):1256–1261.  https://doi.org/10.1056/NEJMra020676 CrossRefPubMedGoogle Scholar
  136. Patzer L (2008) Nephrotoxicity as a cause of acute kidney injury in children. Pediatr Nephrol 23(12):2159–2173.  https://doi.org/10.1007/s00467-007-0721-x CrossRefPubMedGoogle Scholar
  137. Pazhayattil GS, Shirali AC (2014) Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis 7:457–468.  https://doi.org/10.2147/IJNRD.S39747 CrossRefPubMedPubMedCentralGoogle Scholar
  138. Perazella MA (2005) Drug-induced nephropathy: an update. Expert Opin Drug Saf 4(4):689–706.  https://doi.org/10.1517/14740338.4.4.689 CrossRefPubMedGoogle Scholar
  139. Petros WP, Hopkins PJ, Spruill S et al (2005) Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 23(25):6117–6125.  https://doi.org/10.1200/jco.2005.06.075 CrossRefGoogle Scholar
  140. Pianta TJ, Peake PW, Pickering JW, Kelleher M, Buckley NA, Endre ZH (2015) Clusterin in kidney transplantation: novel biomarkers versus serum creatinine for early prediction of delayed graft function. Transplantation 99(1):171–179.  https://doi.org/10.1097/tp.0000000000000256 CrossRefPubMedGoogle Scholar
  141. Piazzon N, Bernet F, Guihard L et al (2015) Urine Fetuin-A is a biomarker of autosomal dominant polycystic kidney disease progression. J Transl Med 13:103.  https://doi.org/10.1186/s12967-015-0463-7 CrossRefPubMedPubMedCentralGoogle Scholar
  142. Price SA, Davies D, Rowlinson R et al (2010) Characterization of renal papillary antigen 1 (RPA-1), a biomarker of renal papillary necrosis. Toxicol Pathol 38(3):346–358.  https://doi.org/10.1177/0192623310362246 CrossRefPubMedGoogle Scholar
  143. Raghavan V, Weisz OA (2016) Discerning the role of mechanosensors in regulating proximal tubule function. Am J Physiol Renal Physiol 310(1):F1–F5.  https://doi.org/10.1152/ajprenal.00373.2015 CrossRefPubMedGoogle Scholar
  144. Reeves WB, Kwon O, Ramesh G (2008) Netrin-1 and kidney injury. I. Netrin-1 is an early biomarker of acute kidney injury. Am J Physiol Renal Physiol 294(4):F731–F738.  https://doi.org/10.1152/ajprenal.00507.2007 CrossRefPubMedGoogle Scholar
  145. Rodriguez-Barbero A, L’Azou B, Cambar J, Löpezlöpez-Novoa JM (2000) Potential use of isolated glomeruli and cultured mesangial cells as in vitro models to assess nephrotoxicity. Cell Biol Toxicol 16:145–153CrossRefGoogle Scholar
  146. Ronco C, Cicoira M, McCullough PA (2012) Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 60:1031–1042.  https://doi.org/10.1016/J.JACC.2012.01.077 CrossRefGoogle Scholar
  147. Rossert J (2001) Drug-induced acute interstitial nephritis. Kidney Int 60(2):804–817.  https://doi.org/10.1046/j.1523-1755.2001.060002804.x CrossRefPubMedGoogle Scholar
  148. Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin Pharmacol Ther 92(1):50–61.  https://doi.org/10.1038/clpt.2012.65 CrossRefPubMedGoogle Scholar
  149. Ryan MJ, Johnson G, Kiiu J, Fuerstenberg SM, Zager RA, Torok-Storb B (1994) HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney. Kidney Int 45:48–57CrossRefGoogle Scholar
  150. Sakairi T, Abe Y, Kajiyama H et al (2010) Conditionally immortalized human podocyte cell lines established from urine. Am J Physiol Renal Physiol 298:F557.  https://doi.org/10.1152/AJPRENAL.00509.2009 CrossRefPubMedGoogle Scholar
  151. Sakolish C, Weber EJ, Kelly EJ et al (2018) technology transfer of the microphysiological systems: a case study of the human proximal tubule tissue chip. Sci Rep 8(1):14882.  https://doi.org/10.1038/s41598-018-33099-2 CrossRefPubMedPubMedCentralGoogle Scholar
  152. Sampathkumar K, Rajiv A, Sampathkumar D (2016) Analgesic nephropathy—a painful progression. Clin Med Insights Urol.  https://doi.org/10.4137/cmu.s13179 CrossRefGoogle Scholar
  153. Sawai K, Mukoyama M, Mori K et al (2007) Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. Am J Physiol Renal Physiol 293(4):F1363–F1372.  https://doi.org/10.1152/ajprenal.00205.2007 CrossRefPubMedGoogle Scholar
  154. Schafer JA, Watkins ML, Li L, Herter P, Haxelmans S, Schlatter E (1997) A simplified method for isolation of large numbers of defined nephron segments. Am J Physiol Renal Physiol 273(4):F650–F657.  https://doi.org/10.1152/ajprenal.1997.273.4.f650 CrossRefGoogle Scholar
  155. Schmouder RL, Strieter RM, Wiggins RC, Chensue SW, Kunkel SL (1992) In vitro and in vivo interleukin-8 production in human renal cortical epithelia. Kidney Int 41:98CrossRefGoogle Scholar
  156. Schutgens F, Rookmaaker MB, Margaritis T et al (2019) Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat Biotechnol 37:303–313.  https://doi.org/10.1038/s41587-019-0048-8 CrossRefPubMedGoogle Scholar
  157. Secker PF, Luks L, Schlichenmaier N, Dietrich DR (2017) RPTEC/TERT1 cells form highly differentiated tubules when cultured in a 3D matrix (1868-596X (Print))Google Scholar
  158. Secker PF, Schlichenmaier N, Beilmann M, Deschl U, Dietrich DR (2019) Functional transepithelial transport measurements to detect nephrotoxicity in vitro using the RPTEC/TERT1 cell line. Arch Toxicol.  https://doi.org/10.1007/s00204-019-02469-8 CrossRefPubMedGoogle Scholar
  159. Shimamoto K, Iimura O (1989) Physiological role of renal kallikrein–kinin system in human. Adv Exp Med Biol 247A:87–96CrossRefGoogle Scholar
  160. Simon-Friedt BR, Wilson MJ, Blake DA, Yu H, Eriksson Y, Wickliffe JK (2015) The RPTEC/TERT1 cell line as an improved tool for in vitro nephrotoxicity assessments. Biol Trace Elem Res 166:66–71.  https://doi.org/10.1007/s12011-015-0339-y CrossRefPubMedPubMedCentralGoogle Scholar
  161. Sjögren A-K, Breitholtz K, Ahlberg E et al (2018) A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery. Arch Toxicol 92:3175–3190.  https://doi.org/10.1007/s00204-018-2284-y CrossRefPubMedGoogle Scholar
  162. Stray KM, Bam RA, Birkus G et al (2013) Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 57(10):4982.  https://doi.org/10.1128/AAC.00712-13 CrossRefPubMedPubMedCentralGoogle Scholar
  163. Takasato M, Er PX, Becroft M et al (2014) Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol 16:118–126.  https://doi.org/10.1038/ncb2894 CrossRefPubMedGoogle Scholar
  164. Takasato M, Er PX, Chiu HS et al (2015) Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 526:564–568.  https://doi.org/10.1038/nature15695 CrossRefGoogle Scholar
  165. Troth SP, Simutis F, Friedman GS, Todd S, Sistare FD (2019) Kidney SAFETY ASSESSMENT: CURRENT PRACTICES IN DRUG DEVELOPMENT. Semin Nephrol 39(2):120–131.  https://doi.org/10.1016/j.semnephrol.2018.12.002 CrossRefPubMedGoogle Scholar
  166. Uehara T, Yamate J, Torii M, Maruyama T (2011) Comparative nephrotoxicity of Cisplatin and nedaplatin: mechanisms and histopathological characteristics. J Toxicol Pathol 24(2):87–94.  https://doi.org/10.1293/tox.24.87 CrossRefPubMedPubMedCentralGoogle Scholar
  167. Uetake R, Sakurai T, Kamiyoshi A et al (2014) Adrenomedullin-RAMP2 system suppresses ER stress-induced tubule cell death and is involved in kidney protection. PLoS One 9(2):e87667.  https://doi.org/10.1371/journal.pone.0087667 CrossRefPubMedPubMedCentralGoogle Scholar
  168. Vaidya VS, Ferguson MA, Bonventre JV (2008a) Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 48:463–493.  https://doi.org/10.1146/annurev.pharmtox.48.113006.094615 CrossRefPubMedPubMedCentralGoogle Scholar
  169. Vaidya VS, Waikar SS, Ferguson MA et al (2008b) Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 1(3):200–208.  https://doi.org/10.1111/j.1752-8062.2008.00053.x CrossRefPubMedPubMedCentralGoogle Scholar
  170. van der Made TK, Fedecostante M, Scotcher D, et al. (2019) Quantitative translation of microfluidic transporter in vitro data to in vivo reveals impaired albumin-facilitated indoxyl sulfate secretion in chronic kidney disease. Mol Pharm.  https://doi.org/10.1021/acs.molpharmaceut.9b00681
  171. van Genderen AM, Jansen J, Cheng C, Vermonden T, Masereeuw R (2018) renal tubular- and vascular basement membranes and their mimicry in engineering vascularized kidney tubules. Adv Healthc Mater 7(19):e1800529.  https://doi.org/10.1002/adhm.201800529 CrossRefPubMedGoogle Scholar
  172. Vervaet BA, D’Haese PC, Verhulst A (2017) Environmental toxin-induced acute kidney injury. Clin Kidney J 10:747–758.  https://doi.org/10.1093/ckj/sfx062 CrossRefPubMedPubMedCentralGoogle Scholar
  173. Vlasakova K, Erdos Z, Troth SP et al (2014) Evaluation of the relative performance of 12 urinary biomarkers for renal safety across 22 rat sensitivity and specificity studies. Toxicol Sci Off J Soc Toxicol 138(1):3–20.  https://doi.org/10.1093/toxsci/kft330 CrossRefGoogle Scholar
  174. Vriend J, Nieskens TTG, Vormann MK et al (2018) screening of drug-transporter interactions in a 3D microfluidic renal proximal tubule on a chip. AAPS J 20:87.  https://doi.org/10.1208/s12248-018-0247-0 CrossRefPubMedGoogle Scholar
  175. Walshe CM, Odejayi F, Ng S, Marsh B (2009) Urinary glutathione S-transferase as an early marker for renal dysfunction in patients admitted to intensive care with sepsis. Crit Care Resusc J Australas Acad Crit Care Med 11(3):204–209Google Scholar
  176. Wang JJ, Chi NH, Huang TM et al (2018) Urinary biomarkers predict advanced acute kidney injury after cardiovascular surgery. Crit Care (London, England) 22(1):108.  https://doi.org/10.1186/s13054-018-2035-8 CrossRefGoogle Scholar
  177. Weber EJ, Chapron A, Chapron BD et al (2016) Development of a microphysiological model of human kidney proximal tubule function. Kidney Int 90(3):627–637.  https://doi.org/10.1016/j.kint.2016.06.011 CrossRefPubMedPubMedCentralGoogle Scholar
  178. Weber EJ, Himmelfarb J, Kelly EJ (2017) Concise review: current and emerging biomarkers of nephrotoxicity. Curr Opin Toxicol 4:16–21.  https://doi.org/10.1016/j.cotox.2017.03.002 CrossRefPubMedPubMedCentralGoogle Scholar
  179. Wei Z, Amponsah PK, Al-Shatti M, Nie Z, Bandyopadhyay BC (2012) Engineering of polarized tubular structures in a microfluidic device to study calcium phosphate stone formation. Lab Chip 12(20):4037–4040.  https://doi.org/10.1039/c2lc40801e CrossRefPubMedPubMedCentralGoogle Scholar
  180. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703.  https://doi.org/10.1634/theoncologist.11-6-694 CrossRefPubMedGoogle Scholar
  181. Wieser M, Stadler G, Jennings P et al (2008) hTERT alone immortalizes epithelial cells of renal proximal tubules without changing their functional characteristics. Am J Physiol Renal Physiol 295(5):F1365–F1375.  https://doi.org/10.1152/ajprenal.90405.2008 CrossRefPubMedGoogle Scholar
  182. Wilmer MJ, Saleem MA, Masereeuw R et al (2010) Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transporters. Cell Tissue Res 339:449–457.  https://doi.org/10.1007/s00441-009-0882-y CrossRefGoogle Scholar
  183. Wilmer MJ, Ng CP, Lanz HL, Vulto P, Suter-Dick L, Masereeuw R (2016) Kidney-on-a-chip technology for drug-induced nephrotoxicity screening. Trends Biotechnol 34:156–170.  https://doi.org/10.1016/j.tibtech.2015.11.001 CrossRefPubMedGoogle Scholar
  184. Wilmes A, Bielow C, Ranninger C et al (2015) Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol In Vitro 30:117–127.  https://doi.org/10.1016/J.TIV.2014.10.006 CrossRefPubMedGoogle Scholar
  185. Wnorowski A, Yang H, Wu JC (2018) Progress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models. Adv Drug Deliv Rev.  https://doi.org/10.1016/j.addr.2018.06.001 CrossRefPubMedGoogle Scholar
  186. Wu C-Y, Yang H-Y, Chien H-P, Tseng M-H, Huang J-L (2018) Urinary clusterin—a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival. Pediatr Nephrol 33(7):1189–1198.  https://doi.org/10.1007/s00467-018-3924-4 CrossRefPubMedGoogle Scholar
  187. Xia Y, Sancho-Martinez I, Nivet E, Rodriguez Esteban C, Campistol JM, Izpisua Belmonte JC (2014) The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. Nat Protoc 9:2693–2704.  https://doi.org/10.1038/nprot.2014.182 CrossRefPubMedGoogle Scholar
  188. Xiao L, Liu Y-P, Xiao C-X, Ren J-L, Guleng B (2014) Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers. BMC Clin Pathol 14:26.  https://doi.org/10.1186/1472-6890-14-26 CrossRefPubMedPubMedCentralGoogle Scholar
  189. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60(5):1645–1657.  https://doi.org/10.1046/j.1523-1755.2001.00032.x CrossRefPubMedGoogle Scholar
  190. Xie HG, Wang SK, Cao CC, Harpur E (2013) Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction. Pharmacol Ther 137(1):100–107.  https://doi.org/10.1016/j.pharmthera.2012.09.004 CrossRefPubMedGoogle Scholar
  191. Yildiz C, Ozsurekci Y, Gucer S, Cengiz AB, Topaloglu R (2013) Acute kidney injury due to acyclovir. CEN Case Rep 2(1):38–40.  https://doi.org/10.1007/s13730-012-0035-0 CrossRefPubMedGoogle Scholar
  192. Yin C, Wang N (2016) Kidney injury molecule-1 in kidney disease. Ren Fail 38(10):1567–1573.  https://doi.org/10.1080/0886022x.2016.1193816 CrossRefPubMedGoogle Scholar
  193. Yu Y, Jin H, Holder D et al (2010) Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol 28(5):470–477.  https://doi.org/10.1038/nbt.1624 CrossRefPubMedGoogle Scholar
  194. Yu S-M, Oh JM, Lee J et al (2018) Substrate curvature affects the shape, orientation, and polarization of renal epithelial cells. Acta Biomater 77:311–321.  https://doi.org/10.1016/j.actbio.2018.07.019 CrossRefPubMedGoogle Scholar
  195. Zajjari Y, Azizi M, Sbitti Y, El Kabbaj D (2017) Nephrotoxicity in a patient treated with pemetrexed. Indian J Nephrol 27(3):243–244.  https://doi.org/10.4103/0971-4065.202403 CrossRefPubMedPubMedCentralGoogle Scholar
  196. Zazuli Z, Otten LS, Drögemöller BI et al (2019) Outcome definition influences the relationship between genetic polymorphisms of ERCC1, ERCC2, SLC22A2 and cisplatin nephrotoxicity in adult testicular cancer patients. Genes (Basel) 10(5):364.  https://doi.org/10.3390/genes10050364 CrossRefGoogle Scholar
  197. Zhao P, Zhang L, Grillo J et al (2011) Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89(2):259–267.  https://doi.org/10.1038/clpt.2010.298 CrossRefPubMedGoogle Scholar
  198. Zhao K-W, Murray EJB, Murray SS (2017) HK2 proximal tubule epithelial cells synthesize and secrete plasma proteins predominantly through the apical surface. J Cell Biochem 118:924–933.  https://doi.org/10.1002/jcb.25786 CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.Division of Pharmacology, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical SciencesUtrecht UniversityUtrechtThe Netherlands
  2. 2.Department of Nephrology and HypertensionUniversity Medical CenterUtrechtThe Netherlands

Personalised recommendations